Historically, two breast cancer subtypes known as invasive lobular carcinoma and ductal carcinoma have been grouped together. They’ve been thought of as having the same screening needs, symptoms, genetic drivers and treatment. But that’s a mistake.

A recently published comprehensive review and new research being presented at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO) by breast medical oncologist Jason...